Scott Marsh Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

Scott Marsh Financial’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$303K	Buy	+578	New	+$323K	0.11%	199

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Scott Marsh Financial's REGN Position: Q2 2025 in Review

Scott Marsh Financial opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2025: 578 shares worth $303K. The stake represents 0.11% of the portfolio and ranks #199 among its holdings.

1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Scott Marsh Financial held 578 shares of Regeneron Pharmaceuticals worth $303K as of Q2 2025.
Regeneron Pharmaceuticals was a new Scott Marsh Financial position in Q2 2025.
Regeneron Pharmaceuticals made up 0.11% of Scott Marsh Financial's portfolio in Q2 2025, its #199 holding.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Scott Marsh Financial's 13F filing for Q2 2025, filed 14 Aug 2025.